WallStSmart

Live Nation Entertainment Inc (LYV)vsVertex Pharmaceuticals Inc (VRTX)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Live Nation Entertainment Inc generates 110% more annual revenue ($25.20B vs $12.00B). VRTX leads profitability with a 32.9% profit margin vs 2.0%. VRTX appears more attractively valued with a PEG of 2.19. VRTX earns a higher WallStSmart Score of 66/100 (B-).

LYV

Hold

47

out of 100

Grade: D+

Growth: 5.3Profit: 5.5Value: 4.0Quality: 3.8
Piotroski: 3/9Altman Z: 1.46

VRTX

Strong Buy

66

out of 100

Grade: B-

Growth: 8.0Profit: 9.0Value: 10.0Quality: 8.0
Piotroski: 3/9Altman Z: 3.62
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for LYV.

VRTXUndervalued (+36.5%)

Margin of Safety

+36.5%

Fair Value

$716.04

Current Price

$454.97

$261.07 discount

UndervaluedFair: $716.04Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

LYV1 strengths · Avg: 10.0/10
Return on EquityProfitability
36.7%10/10

Every $100 of equity generates 37 in profit

VRTX6 strengths · Avg: 9.5/10
Profit MarginProfitability
32.9%10/10

Keeps 33 of every $100 in revenue as profit

Operating MarginProfitability
39.6%10/10

Strong operational efficiency at 39.6%

Altman Z-ScoreHealth
3.6210/10

Safe zone — low bankruptcy risk

Market CapQuality
$113.95B9/10

Large-cap with strong market position

Return on EquityProfitability
22.5%9/10

Every $100 of equity generates 23 in profit

Debt/EquityHealth
0.219/10

Conservative balance sheet, low leverage

Areas to Watch

LYV4 concerns · Avg: 2.5/10
Profit MarginProfitability
2.0%3/10

2.0% margin — thin

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

PEG RatioValuation
7.472/10

Expensive relative to growth rate

Price/BookValuation
133.6x2/10

Trading at 133.6x book value

VRTX3 concerns · Avg: 3.7/10
PEG RatioValuation
2.194/10

Expensive relative to growth rate

P/E RatioValuation
29.3x4/10

Moderate valuation

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

Comparative Analysis Report

WallStSmart Research

Bull Case : LYV

The strongest argument for LYV centers on Return on Equity. Revenue growth of 11.1% demonstrates continued momentum.

Bull Case : VRTX

The strongest argument for VRTX centers on Profit Margin, Operating Margin, Altman Z-Score. Profitability is solid with margins at 32.9% and operating margin at 39.6%.

Bear Case : LYV

The primary concerns for LYV are Profit Margin, Piotroski F-Score, PEG Ratio. Thin 2.0% margins leave little buffer for downturns.

Bear Case : VRTX

The primary concerns for VRTX are PEG Ratio, P/E Ratio, Piotroski F-Score.

Key Dynamics to Monitor

LYV profiles as a value stock while VRTX is a mature play — different risk/reward profiles.

LYV carries more volatility with a beta of 1.15 — expect wider price swings.

LYV is growing revenue faster at 11.1% — sustainability is the question.

VRTX generates stronger free cash flow (349M), providing more financial flexibility.

Bottom Line

VRTX scores higher overall (66/100 vs 47/100), backed by strong 32.9% margins. Both earn "Strong Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Live Nation Entertainment Inc

COMMUNICATION SERVICES · ENTERTAINMENT · USA

Live Nation Entertainment, Inc is an American global entertainment company, founded in 2010, following the merger of Live Nation and Ticketmaster. The company promotes, operates, and manages ticket sales for live entertainment in the United States and internationally. It also owns and operates entertainment venues, and manages the careers of music artists.

Vertex Pharmaceuticals Inc

HEALTHCARE · BIOTECHNOLOGY · USA

Vertex Pharmaceuticals, Inc. is an American biopharmaceutical company based in Boston, Massachusetts.

Want to dig deeper into these stocks?